A research protocol for a randomised parallel study assessing the effect of closed-loop insulin delivery from onset of type 1 diabetes in youth on residual beta-cell function compared to standard insulin therapy has been published in the British Medical Journal, on behalf of the CLOuD Consortium.
The CLOuD study builds on recent technological advances of closed-loop insulin delivery (artificial pancreas). The purpose of this study is to test the impact of continued intensive metabolic control using closed-loop insulin delivery after diagnosis on preservation of C-peptide residual secretion.
The primary objective is to evaluate the effect of continued intensive metabolic control using closed-loop insulin delivery after diagnosis on preservation of C-peptide residual secretion by comparing the area under the stimulated C-peptide curve (AUC) of a mixed meal glucose tolerance test conducted at the 12-month visit in participants receiving closed-loop insulin delivery with those receiving standard therapy, i.e. multiple daily injections applying basal-bolus regimen.
Published April 22, 2020
31-year-old Sameer, who spends more than 70 hours a week on dialysis, says new research results give him hope and highlight the need for more studies in…
An Addenbrooke's-led study is the first to provide clear evidence that using more powerful treatments earlier has long-term benefits for people living with…
Cambridge researchers have discovered that an existing therapy which boosts protective immune cells in people who have recently had heart attacks reduces…